Details of the Drug

General Information of Drug (ID: DM7LOSK)

Drug Name
REGN4018
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0LA9K

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ovarian carcinoma antigen CA125 (MUC16) TTC1PS3 MUC16_HUMAN Inhibitor [2]
T-cell surface glycoprotein CD3 (CD3) TTUN7MC NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Ovarian tissue
The Studied Disease Ovarian cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Ovarian carcinoma antigen CA125 (MUC16) DTT MUC16 4.86E-04 5.02 2.6
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03564340) Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer. U.S. National Institutes of Health.
2 A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.